Surgical Site Infections Pipeline Therapies Analysis 2025: Over 5 Companies Driving Innovation Across 5+ Therapies | DelveInsight

Surgical Site Infections Pipeline Insight 2025: Over 5 Companies Driving Innovation Across 5+ Therapies | DelveInsight
(Albany, United States) According to DelveInsight's analysis, the global Surgical Site Infections pipeline includes more than 5 leading companies actively engaged in the development of over 5 potential SSI therapies. The report provides detailed analysis across clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and recent developmental activities.

DelveInsight's "Surgical Site Infections Pipeline Insight, 2025" report delivers an in-depth evaluation of the current clinical development landscape and future growth opportunities within the Surgical Site Infections (SSI) market.

The Surgical Site Infections Pipeline report offers comprehensive clinical and commercial insights into pipeline candidates ranging from preclinical and discovery stages to marketed products. It includes extensive drug profiles covering mechanisms of action, clinical trial progress, regulatory milestones such as NDA approvals (where applicable), and product development activities. These activities encompass technology platforms, partnerships, mergers and acquisitions, funding updates, regulatory designations, and other key developments related to each product.

Request a sample report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Surgical Site Infections Pipeline Report
• Companies worldwide are actively advancing innovative treatment options for Surgical Site Infections, achieving notable progress over recent years.
• Major players involved in SSI therapy development include MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc., among others.
• Promising SSI therapies currently under various stages of clinical evaluation include Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ointment, E-101, and additional candidates expected to significantly influence the market in the coming years.
• In August 2025, Mayo Clinic researchers created an artificial intelligence (AI) system that can accurately identify surgical site infections (SSIs) from patient-submitted postoperative wound images. Published in Annals of Surgery, this advancement marks significant progress in remote patient monitoring and infection prevention.
• In June 2025, PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company focused on enhancing surgical outcomes, announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100. The therapy, designed to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions, has also received Fast Track designation from the FDA.
• In April 2023, results from the first randomized clinical trial using registry data from the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP®) demonstrated that modifying antibiotic regimens prior to pancreatoduodenectomy (Whipple procedure) reduced SSI incidence.
• In April 2022, Mölnlycke expanded its presence in Malaysia by establishing a new surgical glove manufacturing facility, increasing production capacity to meet growing global demand for Biogel gloves.

Surgical Site Infections Overview
Surgical Site Infections are infections that develop at or near surgical incisions within 30 days after surgery, or up to one year when implants are involved. SSIs are a significant contributor to postoperative complications, leading to prolonged hospital stays, higher healthcare costs, and increased morbidity. These infections may range from superficial wound involvement to deep tissue or organ-space infections.

SSIs are commonly caused by bacterial contamination originating from the patient's skin, surgical tools, or hospital surroundings. Frequently implicated pathogens include Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, and Escherichia coli. Risk factors include extended surgical duration, poor surgical technique, obesity, diabetes, smoking, and compromised immune function.
Typical symptoms include redness, swelling, warmth, pain at the incision site, purulent discharge, fever, and delayed wound healing. Diagnosis relies on clinical evaluation, microbiological cultures, and imaging techniques for suspected deep infections.

Preventive measures involve strict hand hygiene, prophylactic antibiotics, antiseptic skin preparation, adherence to sterile surgical practices, and proper postoperative wound care. Management strategies include wound drainage, debridement, and targeted antibiotic therapy, with additional surgical intervention required in severe cases.

Reducing the burden of SSIs remains a key priority for healthcare systems, with strong emphasis placed on infection prevention and control protocols to enhance patient outcomes.

Access a free sample PDF report: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Surgical Site Infections Therapies by Development Stage
• Ciprodiazole - MinaPharm Pharma
• DFA-02 - Duke Clinical Research
• ZuraPrep - Zurex Pharma, Inc.
• Ertapenem - Merck Sharp & Dohme LLC
• XF-73 - Destiny Pharma Plc
• D-PLEX - PolyPid Ltd.
• Dalbavancin - Durata Therapeutics
• BACTROBAN® Nasal ointment - Lindenhofgruppe AG
• E-101 - Veristat, Inc.

Surgical Site Infections Route of Administration Analysis
The report evaluates SSI pipeline therapies based on various routes of administration, including:
• Inhalation
• Inhalation / Intravenous / Oral
• Intranasal
• Intravenous
• Intravenous / Subcutaneous
• Oral
• Oral / Intranasal / Subcutaneous
• Parenteral
• Subcutaneous
• Not Applicable (NA)

Surgical Site Infections Molecule Type Classification
Surgical Site Infections pipeline products are categorized by molecule type, such as:
• Antibodies
• Antisense oligonucleotides
• Immunotherapies
• Monoclonal antibodies
• Peptides
• Proteins
• Recombinant proteins
• Small molecules
• Stem cell therapies
• Vaccines

Surgical Site Infections Therapeutic Assessment
• Evaluation by product type
• Assessment by development stage and product type
• Analysis by route of administration and development stage
• Assessment by molecule type and clinical stage
DelveInsight's report profiles over five SSI pipeline products across multiple stages, including Phase III, Phase II, Phase I, preclinical, discovery-stage, and discontinued or inactive candidates, along with their respective routes of administration.
Comprehensive product-level insights are provided throughout the report. Stakeholders can download the Surgical Site Infections Pipeline Insight report to gain deeper understanding of emerging SSI therapies.

Download the sample report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Surgical Site Infections Therapeutics Market
Major companies contributing to the SSI treatment landscape include Becton, Dickinson and Company, 3M Company, bioMérieux SA, Getinge Group, Johnson & Johnson, and others.

Surgical Site Infections Pipeline Analysis
The report provides:
• Detailed company-level insights into SSI therapy development portfolios
• Segmentation of drug candidates into early-, mid-, and late-stage development
• Analysis of active, inactive, and discontinued programs
• Classification based on development stage, route of administration, target receptors, monotherapy or combination approaches, mechanisms of action, and molecular types
• Comprehensive evaluation of collaborations, licensing deals, and funding activities supporting future market growth
The analysis is developed using data sourced from DelveInsight's proprietary databases, company and academic websites, clinical trial registries, scientific conferences, SEC filings, investor presentations, and industry-specific third-party resources.
Surgical Site Infections Market Drivers
• Increasing surgical procedures, a growing elderly population, and rising concern over hospital-acquired infections are key factors driving growth in the Surgical Site Infections market.

Surgical Site Infections Market Challenges
• Limited awareness of infection prevention measures, challenges in accurately identifying infection sites, and related issues pose barriers to market expansion.

Scope of the Surgical Site Infections Pipeline Insight
• Geographic Coverage: Global
• Key Companies: MinaPharm Pharma, Duke Clinical Research, Zurex Pharma, Inc., Merck Sharp & Dohme LLC, Destiny Pharma Plc, PolyPid Ltd., Durata Therapeutics, Lindenhofgruppe AG, Veristat, Inc., and others
• Key Therapies: Ciprodiazole, DFA-02, ZuraPrep, Ertapenem, XF-73, D-PLEX, Dalbavancin, BACTROBAN® Nasal ointment, E-101, among others
• Therapeutic Coverage: Marketed and emerging SSI therapies
• Market Dynamics: Drivers and barriers influencing the SSI pipeline market

Request a free sample PDF report for detailed clinical trial and pipeline insights: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.